References
- Wells CD, Cegielski JP, Nelson LJ, et al. HIV infection and multidrug-resistant tuberculosis—The perfect storm. J Infect Dis. 2007;196(s1):S86–107. doi: 10.1086/518665.
- World Health Organization. Global tuberculosis report. World Health Organization; 2014. Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf?ua=1.
- Castillo-Chavez C, Feng Z. To treat or not to treat: the case of tuberculosis. J Math Biol. 1997;35:629–56.10.1007/s002850050069
- Harris T, Peer S, Fagan JJ. Audiological monitoring for ototoxic tuberculosis, human immunodeficiency virus and cancer therapies in a developing world setting. J Laryngol Otol. 2012;548–51. doi: 10.1017/S0022215112000357. PubMed PMID: 22459550.
- World Health Organization. Gentamicin-ototoxicity in children. In Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines. 2008; Geneva: World Health Organization. p. 1–6. Available from: http://www.who.int/selection_medicines/committees/subcommittee/2/gentamicin_rev.pdf.
- Kramer SJ. Audiology: science to practice. London: Plural Publishing; 2008.
- Seddon JA, Godfrey-Faussett P, Jacobs K, et al. Hearing loss in patients on treatment for drug-resistant tuberculosis. Eur Resp J. 2012;40:1277–86. doi: 10.1183/09031936.00044812.
- Appana D. An audiological profile of patients infected with multi-drug resistant tuberculosis at a district hospital in Kwa-Zulu Natal. 2013. (Unpublished Masters Dissertation). University of KwaZulu-Natal.
- Campbell KCM. Audiological monitoring for ototoxcity. In: Roland PS, Rutka JA, editors. Ototoxicity. Hamilton: B C Decker; 2004. p. 153–161.
- Konrad-Martin D, Wilmington DJ, Gordon JS, et al. Audiological management of patients receiving aminoglycoside antibiotics. Volta Rev. 2005;105(3):229–50.
- American Academy of Audiology. Position statement and clinical guidelines: ototoxicity monitoring. American Academy of Audiology; 2009. Available from: http://www.google.co.za/url?sa=t&rct=j&q=Position+Statement+and+Clinical+Guidelines:+Ototoxicity+Monitoring&source=web&cd=1&cad=rja&ved=0CDEQFjAA&url=http%3A%2F%2Fwww.audiology.org%2Fresources%2Fdocumentlibrary%2Fdocuments%2Fotomonpositionguideline.pdf&ei.
- American Speech-Language-Hearing Association. Audiologic management of individuals receiving cochleotoxic drug therapy. 1994. Available from: http://www.asha.org/policy/GL1994-00003/.
- Department of Health. Management of drug-resistant tuberculosis: policy guidelines. 2010 Aug. Available from: http://www.tbonline.info/media/uploads/documents/mdr-tb_sa_2010.pdf.
- Health Professions Council of South Africa. A guideline for planning STA services at all levels of health care. 2014. Available from: http://www.hpcsa.co.za/Uploads/editor/UserFiles/downloads/speech/guidelines/guideline_planning_STA_services_at_all_levels_health%20care.pdf.
- Harris T, Bardien S, Schaaf SH, et al. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S Afr Med J. 2012 Jun;102(6):363–66.
- Naidoo T. Wits institutional repository on DSpace. 2006. Available from: http://wiredspace.wits.ac.za/808CD5A6-40FF-474C-BACE-7BDE473CA7F1/FinalDownload/DownloadId-6C11CF1CE10D594E382053DAE8215336/808CD5A6-40FF-474C-BACE-7BDE473CA7F1/bitstream/handle/10539/4515/tirusha%20naidoo%20masters%202006%20PDF.pdf?sequence=2.
- Bernard F. SA health info [Internet]. 2011. Available from: http://www.sahealthinfo.org/tb/tbburden.htm.
- Campbell KCM. Pharmacology in audiology. In: Roeser RJ, Valente M, Hosford-Dunn H, editors. Audiology diagnosis. 2nd ed. New York: Thieme Medical; 2011. p. 157–94.
- Duggal P, Sarkar M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. Bio Med Center Ear Nose Throat Disorders. 2007;7(5):1472–7.
- Fausti SA, Helt WJ, Phillips DS, et al. Early detection of ototoxicity using 1/6th-octave steps. J Am Acad Audiol. 2003;14(8):444–50.
- Mattucci KF, Vasquez R. A proposed protocol for monitoring ototoxicity in patients who take cochleo- or vestibulotoxic drugs. Ear Nose Throat J. 2003;82(3):181–4.
- Venter K. University of Canterbury. 2011. Available from: http://hdl.handle.net/10092/5572.